CME/CE

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

This educational program consists of 10 presentations on once-weekly basal insulin.

Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time.

Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland.

Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.

This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.

Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.